Cencora, Inc. (NYSE:COR) Receives Average Recommendation of “Moderate Buy” from Analysts

Cencora, Inc. (NYSE:COR) has received a consensus rating of “Moderate Buy” from the eight brokerages that are currently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $258.13.

Several equities analysts have weighed in on the company. Leerink Partners restated an “outperform” rating and set a $275.00 target price on shares of Cencora in a report on Thursday, June 27th. JPMorgan Chase & Co. raised their target price on Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a report on Wednesday, August 21st. StockNews.com upgraded Cencora from a “buy” rating to a “strong-buy” rating in a report on Friday, August 2nd. Robert W. Baird cut their target price on Cencora from $287.00 to $283.00 and set an “outperform” rating on the stock in a report on Friday, September 6th. Finally, Wells Fargo & Company lifted their price objective on Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 1st.

Insider Buying and Selling at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,473 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total value of $357,482.37. Following the completion of the transaction, the executive vice president now owns 10,948 shares of the company’s stock, valued at approximately $2,656,970.12. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Cencora news, CEO Steven H. Collis sold 10,755 shares of the company’s stock in a transaction that occurred on Tuesday, July 16th. The stock was sold at an average price of $222.12, for a total value of $2,388,900.60. Following the completion of the transaction, the chief executive officer now owns 285,088 shares of the company’s stock, valued at approximately $63,323,746.56. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Silvana Battaglia sold 1,473 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total value of $357,482.37. Following the completion of the transaction, the executive vice president now directly owns 10,948 shares of the company’s stock, valued at approximately $2,656,970.12. The disclosure for this sale can be found here. Insiders sold a total of 4,450,399 shares of company stock valued at $1,070,392,799 in the last quarter. Corporate insiders own 15.80% of the company’s stock.

Hedge Funds Weigh In On Cencora

Several large investors have recently added to or reduced their stakes in COR. Rise Advisors LLC bought a new stake in shares of Cencora in the 1st quarter valued at approximately $25,000. New Millennium Group LLC bought a new stake in shares of Cencora in the 2nd quarter valued at approximately $26,000. Legacy Bridge LLC bought a new stake in shares of Cencora in the 1st quarter valued at approximately $27,000. TCTC Holdings LLC bought a new stake in shares of Cencora in the 1st quarter valued at approximately $29,000. Finally, TFO Wealth Partners LLC bought a new stake in shares of Cencora in the 1st quarter valued at approximately $30,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Price Performance

COR opened at $234.53 on Wednesday. The stock has a market cap of $46.78 billion, a price-to-earnings ratio of 25.66, a PEG ratio of 1.55 and a beta of 0.44. Cencora has a 1 year low of $177.00 and a 1 year high of $247.66. The company has a current ratio of 0.89, a quick ratio of 0.55 and a debt-to-equity ratio of 3.93. The stock has a fifty day moving average price of $234.52 and a 200 day moving average price of $233.26.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.18 by $0.16. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The firm had revenue of $74.20 billion during the quarter, compared to analysts’ expectations of $73.32 billion. During the same quarter last year, the firm earned $2.92 earnings per share. The business’s revenue for the quarter was up 10.8% on a year-over-year basis. Analysts forecast that Cencora will post 13.63 EPS for the current fiscal year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 9th were paid a $0.51 dividend. The ex-dividend date of this dividend was Friday, August 9th. This represents a $2.04 dividend on an annualized basis and a dividend yield of 0.87%. Cencora’s payout ratio is presently 22.32%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.